Literature DB >> 11240016

Reduction in glial immunity and neuropathology by a PAF antagonist and an MMP and TNFalpha inhibitor in SCID mice with HIV-1 encephalitis.

Y Persidsky1, J Limoges, J Rasmussen, J Zheng, A Gearing, H E Gendelman.   

Abstract

The effects of anti-inflammatory drugs on glial immunity and neuropathology were determined in a severe combined immune deficiency (SCID) mouse model of HIV-1 encephalitis. HIV-1-infected human monocyte-derived macrophages (MDM) are stereotactically inoculated into basal ganglia resulting in a multinucleated giant cell encephalitis. A platelet activating factor antagonist and a matrix metalloproteinase inhibitor, which also inhibits tumor necrosis factor alpha release, were administered to animals at the time of the MDM inoculation. The drugs administered in combination markedly reduced brain inflammation, astrogliosis and microglia activation. These findings demonstrate that reduction of brain inflammatory responses, independent of viral replication, can affect HIVE pathology in an animal model system of disease.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11240016     DOI: 10.1016/s0165-5728(00)00454-9

Source DB:  PubMed          Journal:  J Neuroimmunol        ISSN: 0165-5728            Impact factor:   3.478


  26 in total

Review 1.  Rodent models for HIV-associated neurocognitive disorders.

Authors:  Santhi Gorantla; Larisa Poluektova; Howard E Gendelman
Journal:  Trends Neurosci       Date:  2012-02-01       Impact factor: 13.837

2.  PPARα and PPARγ protect against HIV-1-induced MMP-9 overexpression via caveolae-associated ERK and Akt signaling.

Authors:  Wen Huang; Ibolya E András; Geun Bae Rha; Bernhard Hennig; Michal Toborek
Journal:  FASEB J       Date:  2011-08-12       Impact factor: 5.191

3.  Mononuclear phagocyte differentiation, activation, and viral infection regulate matrix metalloproteinase expression: implications for human immunodeficiency virus type 1-associated dementia.

Authors:  A Ghorpade; R Persidskaia; R Suryadevara; M Che; X J Liu; Y Persidsky; H E Gendelman
Journal:  J Virol       Date:  2001-07       Impact factor: 5.103

Review 4.  Neuropsychiatric manifestations of HIV infection and AIDS.

Authors:  Benoit Dubé; Tami Benton; Dean G Cruess; Dwight L Evans
Journal:  J Psychiatry Neurosci       Date:  2005-07       Impact factor: 6.186

5.  Novel delivery system enhances efficacy of antiretroviral therapy in animal model for HIV-1 encephalitis.

Authors:  Timothy J Spitzenberger; David Heilman; Casey Diekmann; Elena V Batrakova; Alexander V Kabanov; Howard E Gendelman; William F Elmquist; Yuri Persidsky
Journal:  J Cereb Blood Flow Metab       Date:  2006-10-25       Impact factor: 6.200

6.  PPARalpha and PPARgamma attenuate HIV-induced dysregulation of tight junction proteins by modulations of matrix metalloproteinase and proteasome activities.

Authors:  Wen Huang; Sung Yong Eum; Ibolya E András; Bernhard Hennig; Michal Toborek
Journal:  FASEB J       Date:  2009-01-13       Impact factor: 5.191

7.  Neuroprotective activities of CEP-1347 in models of neuroAIDS.

Authors:  Dawn Eggert; Prasanta K Dash; Santhi Gorantla; Huanyu Dou; Giovanni Schifitto; Sanjay B Maggirwar; Stephen Dewhurst; Larisa Poluektova; Harris A Gelbard; Howard E Gendelman
Journal:  J Immunol       Date:  2009-12-04       Impact factor: 5.422

8.  Platelet Activating Factor (PAF) Receptor Deletion or Antagonism Attenuates Severe HSV-1 Meningoencephalitis.

Authors:  Márcia Carvalho Vilela; Graciela Kunrath Lima; David Henrique Rodrigues; Norinne Lacerda-Queiroz; Vinicius Sousa Pietra Pedroso; Aline Silva de Miranda; Milene Alvarenga Rachid; Erna Geessien Kroon; Marco Antônio Campos; Mauro Martins Teixeira; Antonio Lucio Teixeira
Journal:  J Neuroimmune Pharmacol       Date:  2016-05-19       Impact factor: 4.147

Review 9.  CNS inflammation and macrophage/microglial biology associated with HIV-1 infection.

Authors:  Anjana Yadav; Ronald G Collman
Journal:  J Neuroimmune Pharmacol       Date:  2009-09-19       Impact factor: 4.147

10.  Human immunodeficiency virus type-1 protein Tat induces tumor necrosis factor-alpha-mediated neurotoxicity.

Authors:  Lara Buscemi; David Ramonet; Jonathan D Geiger
Journal:  Neurobiol Dis       Date:  2007-03-20       Impact factor: 5.996

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.